MarketPulse

Phase 2 ACUITY trial

3 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Oculis Scores EMA PRIME Designation for Optic Neuritis Drug Privosegtor

Oculis' neuroprotective candidate Privosegtor receives EMA PRIME designation for optic neuritis, following FDA Breakthrough designation and positive Phase 2 data.
OCSOCSAWrare diseaseorphan drug
GlobeNewswire Inc.GlobeNewswire Inc.··Oculis Holding Ag

Oculis to Present Pivotal Optic Neuritis Data as Privosegtor Advances Toward FDA Review

Oculis presents Phase 2 data for Privosegtor, an FDA Breakthrough-designated optic neuritis therapy showing improved visual acuity and reduced nerve damage, advancing toward Phase 3 registration trial.
OCSOCSAWFDA Breakthrough Therapy DesignationPrivosegtor
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Oculis to Showcase Optic Neuritis Data as Privosegtor Advances to Pivotal Trials

Oculis presents Phase 2 ACUITY trial results for Privosegtor at neuro-ophthalmology conference, showing vision improvements. Breakthrough therapy advances to registrational PIONEER program.
OCSOCSAWPrivosegtoroptic neuritis